Clinical trial Recruiting at 1 site Interventional Ages 8 to 12

How classroom indoor air affects children's allergies and wellbeing

Official title: Disrupting Noxious Synergies of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing, Using Advanced Intelligent Multisensing and Green Interventions: an Interventional Study in a Sub-group of Schoolchildren

Run by University Hospital, Montpellier · NCT07402200 · Data updated 2026-11-12

This project will test whether continuous classroom and home air pollutant monitoring can identify pollution patterns linked to worse allergy or asthma symptoms in school-age children.

Quick facts

Study typeInterventional
Ages8 Years to 12 Years
SexAll
Enrollment100 (estimated)
SponsorUniversity Hospital, Montpellier
Academic / other
Locations1 site (Montpellier)
StatusRecruiting
StartedFebruary 4, 2026
Main results expectedJune 2026
Study endsJune 2026
Registry record updatedFebruary 11, 2026
Trial IDNCT07402200 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

School-aged children already enrolled in the SynAir-G observational study whose parents or guardians provide written informed consent, especially those with a history of allergic disease or asthma, are ideal candidates.

Probably not a fit

Children not enrolled in SynAir-G, those unable to comply with follow-up visits or sensor monitoring, and children without allergic or asthmatic symptoms may derive little direct benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will enroll children already in the SynAir-G observational cohort and classify them as cases or controls based on baseline questionnaire responses about asthma and allergic symptoms. Participants and caregivers will complete standardized questionnaires while children undergo skin prick allergy tests, non-invasive lung function tests, oxygen saturation checks, and provide biological samples as appropriate. Portable sensors placed in classrooms (and optionally at home) will continuously measure multiple air and dust pollutants to create individualized exposure baselines and detect changes over time. Health outcomes including respiratory symptoms, immune markers, and quality-of-life measures will be compared to the continuous exposure data to identify pollutant patterns associated with worsening or improvement.

Why it matters

Potential benefit: If successful, this approach could enable earlier detection of harmful exposures and targeted actions to reduce pollutants and improve allergy and asthma control in affected children.

How similar studies have gone: Prior studies have linked air pollution to worsened asthma and allergy outcomes, but the use of continuous, individualized classroom and home sensor data to link pollutant patterns to individual health outcomes is relatively novel and not yet widely proven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Child included in the SynAir-G observational study
* Child and caregiver(s) willing to follow the study procedures
* Written informed consent from the child's parents/guardians
* For case group, at least one positive answer (yes) to any of the following questions and for control group, negative answers to all the following questions based on the baseline questionnaire administered in the SynAir-G observational study, as shown below.:

  a. General health i. Does your child have any health problems (if yes to asthma, allergic rhinitis /rhino-conjunctivitis, atopic dermatitis)? b. Asthma i. Has your child ever had wheezing or whistling in the chest in the past 12 months? ii. In the past 12 months, has your child's chest sounded wheezy during or after exercise? iii. In the past 12 months, has your child had a dry cough at night, apart from a cough associated with a cold or chest infection? c. Rhinitis i. In the past 12 months has your child had a problem with sneezing, or a runny, or blocked nose when she/he DID NOT have a cold or the flu? d. Eczema (both answers yes) i. Has your child had this itchy rash at any time in the past 12 months? If so, has this itchy rash at any time affected any of the following places: the folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes? e. Food allergy i. Has your child had diagnosed food allergy during last 12 months?
* For case group: Diagnosis of asthma/allergic rhinitis/eczema/food allergy (based on SYNAIR-G baseline questionnaire), active during the past year.
* For control group: absence of diagnosis of asthma/allergic rhinitis/eczema/food allergy (based on SYNAIR-G baseline questionnaire)

Exclusion Criteria:

* Child or child's parents/guardians who:

  1. Refuse to participate in the project / to give informed consent.
  2. Do not want to follow the protocol procedures.
  3. Do not read or/and write in French.
  4. Plan a long stay outside the region that does not allow them to follow the visit plan.
  5. The child is not affiliated to the French social security service

Where it's running

  • CHU Montpellier
    Montpellier, France
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • What the Mayo Clinic is learning from blood clot tests in allergic reactions

    This study tests whether real-time blood clotting markers can help understand and predict the severity of allergic reactions and anaphylaxis in patients 12 and older.

    Recruiting Mayo Clinic · Rochester, Minnesota · NCT07905911

  • Does having allergic parents raise the chance of bronchiolitis in babies by 12 months?

    We’re testing if infants with at least one allergic parent are more likely to have bronchiolitis by 12 months compared to infants whose parents have no allergies.

    Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT07832643

  • Using alpha-gal KO pork to see if it reduces reactions in people with Alpha-gal Syndrome

    This study tests whether eating pork that lacks the alpha-gal allergen lowers reaction risk for people with Alpha-gal Syndrome, using a crossover design where each participant tries both KO and wild-type pork on separate days.

    Recruiting Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Little Rock, Arkansas and 3 other locations · NCT07611435

  • Lymph node examination during cat allergy immunotherapy

    This project will test how lymph nodes react after a small cat allergen skin challenge in people with cat allergy who are either on long-term allergy shots or have never had immunotherapy.

    Recruiting Early Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Boston, Massachusetts · NCT07447869

  • Beltaven shots for allergy to honeybee, paper wasp, or yellow jacket

    This project will try subcutaneous Beltaven allergy shots in people aged 14 and up who have had systemic reactions to Apis mellifera, Polistes dominula, or Vespula stings to see if they are safe and helpful in routine care.

    Recruiting at 13 sites Probelte Pharma S.L.U. · Barcelona, Barcelona and 12 other locations · NCT07309822

  • Biomarkers that predict peanut allergy reactions during a feeding test

    This study tests whether biomarkers can predict which children and teens will react during a peanut oral food challenge.

    Recruiting at 8 sites National Institute of Allergy and Infectious Diseases (NIAID) · Little Rock, Arkansas and 9 other locations · NCT07279467

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.